Showing results (581-590 of 6,299) with videos related to
Sort By:
Pageof 630
Diabetes, Obesity & Metabolism|July 14, 2018
Triglyceride-rich very low-density lipoproteins (VLDL) are independently associated with insulin secretion in a multiethnic cohort of adolescentsDomenico Tricò, Andrea Natali, Andrea Mari, et al.Diabetes, Obesity & Metabolism|June 5, 2018
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programmeJ Hans DeVries, Cyrus Desouza, Srikanth Bellary, et al.Diabetes, Obesity & Metabolism|July 3, 2018
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trialMartin Ridderstråle, Julio Rosenstock, Knut R Andersen, et al.Diabetes, Obesity & Metabolism|September 13, 2016
Cell fate conversion-from the viewpoint of small molecules and lineage specifiersT Zhao, Y Li, H DengDiabetes, Obesity & Metabolism|September 13, 2016
Role of long non-coding RNAs in the determination of β-cell identityA Motterle, C Sanchez-Parra, R RegazziDiabetes, Obesity & Metabolism|September 13, 2016
β-Cell adaptation in pregnancyL Baeyens, S Hindi, R L Sorenson, et al.Diabetes, Obesity & Metabolism|September 13, 2016
Novel factors modulating human β-cell proliferationJ Shirakawa, R N KulkarniDiabetes, Obesity & Metabolism|September 13, 2016
Mechanisms of adult human β-cell in vitro dedifferentiation and redifferentiationS EfratDiabetes, Obesity & Metabolism|September 13, 2016
β-Cell dysfunction in diabetes: a crisis of identity?M F Brereton, M Rohm, F M AshcroftDiabetes, Obesity & Metabolism|May 12, 2017
Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled studyJohn Marcinak, Charles Cao, Douglas Lee, et al.Pageof 630